BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and immuno-modulatory antibodies for cancer therapy. The company is headquartered in Lund, Skane and currently employs 122 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Follow-Up Questions
BOVNF hissesinin fiyat performansı nasıl?
BOVNF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
BioInvent International AB için ana iş temaları veya sektörler nelerdir?
BioInvent International AB Biotechnology endüstrisine ait ve sektör Health Care 'dir
BioInvent International AB 'in piyasa değerlemesi nedir?
BioInvent International AB 'in mevcut piyasa değerlemesi $0 'dir
BioInvent International AB al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist BioInvent International AB için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 5 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
